In more than fifteen years working on the infrastructure behind clinical research, I have found that few topics in the biologics conversation cause as much confusion as biosimilar interchangeability. The word sounds technical, but it carries real consequences for competition, pricing, and how patients get their medicines. Because so much of my work touches the infrastructure that supports biosimilar development, I want to explain interchangeability clearly, separate it from common misconceptions, and describe how the rules are changing in a way that could reshape the market.
What Is Biosimilar Interchangeability?
To understand interchangeability, start with what a biosimilar is. A biosimilar is a biologic that is highly similar to an already approved biologic, known as the reference product, with no clinically meaningful differences in safety or effectiveness. Biosimilars go through a rigorous approval process built on extensive analytical and clinical comparison. If you want the foundation, I have written about the role of biologics in medicine and the regulatory pathways for biosimilar approval.
Interchangeability is an additional regulatory designation in the United States. An interchangeable biosimilar is one that the Food and Drug Administration has determined may be substituted for the reference product at the pharmacy level without involving the prescriber, in the same way a pharmacist can substitute a generic for a brand name drug, subject to state law.
Here is the key point that trips people up. Interchangeability is a statement about pharmacy substitution, not about clinical quality. It does not mean an interchangeable biosimilar is safer or more effective than a standard biosimilar. It means it has met an additional standard that permits automatic substitution.
Biosimilar Versus Interchangeable Biosimilar
So are a biosimilar and an interchangeable biosimilar different products? Not in the way most people assume.
Both are approved as highly similar to the reference product with no clinically meaningful differences. A physician can prescribe either one with confidence. The difference is purely about substitution. With a standard biosimilar, a pharmacist generally cannot swap it for the prescribed product without contacting the prescriber. With an interchangeable biosimilar, the pharmacist can make that substitution automatically, again subject to state pharmacy laws.
This distinction has caused an unfortunate side effect. Because only some biosimilars carried the interchangeable label, some prescribers wrongly assumed interchangeable products were of higher quality. The FDA has been clear that this is a misunderstanding. All biosimilars meet the same rigorous approval standard.
How a Biosimilar Historically Earned Interchangeable Status
Under the original framework, earning the interchangeable designation required more than the standard biosimilar approval. A developer typically had to run a switching study, which tested whether patients could alternate between the biosimilar and the reference product without a loss of safety or effectiveness.
These studies added time and cost to development. They also created a two tier perception in the market, where interchangeable products looked different from other biosimilars even though the underlying science supporting all biosimilars is the same. For a market already struggling to realize its full savings potential, that extra burden was a real barrier.
What Changed: The FDA Shift in 2024 and 2025
The regulatory picture has been moving quickly, and it is worth being precise about it.
In June 2024, the FDA issued draft guidance that lowered the barrier to the interchangeable designation. Rather than requiring a dedicated switching study in most cases, the guidance indicated that the agency could accept an assessment of the comparative analytical and clinical data already generated to support the switching standard. In practice, that made it far easier for a biosimilar to be considered interchangeable.
The direction continued in 2025. In late October 2025, the FDA announced additional draft guidance aimed at simplifying biosimilar development and reducing unnecessary clinical testing. In public statements around that announcement, agency leaders repeatedly emphasized that all biosimilars should be considered interchangeable with their reference products. The FDA also signaled, as a policy priority, that the interchangeability distinction could be eliminated altogether, which would require action from Congress to fully implement.
The agency has also questioned the value of certain costly studies. It noted that comparative efficacy studies, despite requiring one to three years and costing roughly twenty four million dollars on average, generally have low sensitivity compared with modern analytical methods. That reasoning underpins the broader push to streamline development. For the current official position, the FDA maintains a public overview of biosimilar and interchangeable biologics.
It is important to note that draft guidance reflects the agency’s current thinking and is not final rule. The trajectory, however, is clear. The regulatory framework is moving toward treating interchangeability as the norm rather than a special category.
Interchangeability and Pharmacy Substitution
Even where the FDA grants interchangeable status, actual substitution at the pharmacy is governed by state law. Most states have enacted biosimilar substitution laws, but the specifics vary. Some require the pharmacist to notify the prescriber after a substitution, some require patient consent, and some impose recordkeeping requirements.
For patients and providers, the practical takeaway is simple. Whether a substitution happens depends on both the federal designation and the rules of the state where the prescription is filled. Any decision about switching a specific patient’s therapy is a clinical one that should involve the prescriber and pharmacist.
Why Interchangeability Matters for Costs
Interchangeability is not an academic detail. It affects how quickly biosimilars can build the market share that produces savings.
The financial stakes are large. According to industry analysis, biosimilars alone generated about twenty billion dollars in savings in 2024, and more than fifty billion dollars cumulatively since the first biosimilar launched in 2015. Generic and biosimilar medicines together saved the United States health system hundreds of billions of dollars in a single year. Looking ahead, well over one hundred biologics are expected to lose exclusivity over the coming decade, representing a savings opportunity estimated in the hundreds of billions of dollars, according to reports such as the Association for Accessible Medicines savings report.
Those savings are not automatic. They depend on biosimilars actually being adopted, and easier substitution supports adoption. When interchangeability is simpler and more consistent, biosimilars can reach patients faster and competition can do its work on price. This is the same theme that runs through much of my writing. Policy sets direction, but execution and infrastructure determine whether the savings are realized, which starts with reliable access to comparators through sound clinical trial supply chain management and disciplined comparator sourcing.
What It Means for Patients and Providers
For patients, the practical message is reassuring. A biosimilar, whether labeled interchangeable or not, has met a rigorous FDA standard and can be trusted when prescribed. Interchangeability affects how a prescription may be filled, not whether the medicine works.
For providers and pharmacists, the evolving rules mean that more biosimilars are likely to be substitutable over time, which can simplify access and reduce cost for patients. Staying current with both federal designations and state substitution laws remains part of responsible practice.
The Road Ahead
The clearest trend is convergence. The distinction between biosimilar and interchangeable biosimilar, which once required expensive extra studies, is being narrowed and may eventually disappear. If that happens, the market moves closer to the generic model, where approved equivalents can be substituted routinely and competition drives prices down.
Getting there still depends on the unglamorous work behind the scenes. Biosimilar trials need reliable access to reference products, disciplined supply chains, and rigorous quality. Those foundations do not make headlines, but they are what allow regulatory reform to translate into real savings.
Common Myths About Biosimilars and Interchangeability
Because the topic is confusing, a few myths persist, and they are worth correcting directly.
The first myth is that interchangeable biosimilars are higher quality. They are not. Interchangeability is about pharmacy substitution, not clinical merit. Every approved biosimilar meets the same rigorous standard.
The second myth is that a biosimilar is a generic. It is not. Generics are chemically identical copies of small molecule drugs. Biologics are large, complex molecules made in living systems, so a biosimilar is highly similar rather than identical, which is exactly why the approval science is so thorough. I unpack this fully in my piece on the differences between biosimilars and generics.
The third myth is that switching between a biosimilar and its reference product is risky. The accumulated evidence, and the direction of FDA policy, indicate that switching does not raise safety or efficacy concerns for approved biosimilars. That evidence base is precisely why the agency has moved to relax switching study requirements.
The fourth myth is that biosimilars have already delivered all the savings they can. In reality, a large wave of biologics is only now approaching loss of exclusivity, and much of the savings opportunity lies ahead, provided biosimilars are actually developed and adopted for those products.
The Pharmacist’s Expanding Role
As interchangeability becomes more common, pharmacists take on a larger part in realizing biosimilar savings. When a biosimilar is interchangeable and state law permits, a pharmacist can substitute it much as they would a generic, which speeds adoption and lowers cost at the point of care.
That role comes with responsibility. Pharmacists have to track which products are interchangeable, follow their state’s notification and consent rules, and communicate clearly with patients who may be unfamiliar with biosimilars. Good communication matters, because patient confidence affects whether a substitution is accepted. As the framework simplifies, the pharmacy counter becomes one of the places where policy reform turns into practical savings.
How Interchangeability Differs Outside the United States
It is worth remembering that interchangeability, as a formal designation, is largely a United States concept. In the European Union, for example, the central regulator evaluates biosimilars for approval but has historically left decisions about substitution and interchangeability to individual member states. The result is a patchwork of national practices rather than a single interchangeable label.
This matters for anyone working across markets. A biosimilar strategy that assumes the United States framework will not translate cleanly to other regions, where the science of biosimilarity is shared but the substitution rules are set locally. For the global supply and development side of the business, understanding these differences is part of planning a program that works everywhere it needs to, not just at home.
Frequently Asked Questions
What is biosimilar interchangeability?
It is a United States regulatory designation indicating that a biosimilar may be substituted for its reference product at the pharmacy without prescriber involvement, subject to state law. It concerns pharmacy substitution, not clinical quality.
Is an interchangeable biosimilar better than a regular biosimilar?
No. Both meet the same rigorous FDA standard of high similarity with no clinically meaningful differences. Interchangeability only affects whether a pharmacist can substitute the product automatically.
What is the difference between a biosimilar and an interchangeable biosimilar?
The clinical standard is the same for both. The difference is that an interchangeable biosimilar can be substituted at the pharmacy without contacting the prescriber, while a standard biosimilar generally cannot.
Did the FDA change the interchangeability rules?
Yes. Draft guidance in June 2024 reduced the need for dedicated switching studies, and further draft guidance in late 2025 signaled that all biosimilars should be considered interchangeable, with the agency proposing that the distinction could eventually be removed. These are draft policies reflecting the agency’s current thinking.
Does interchangeability depend on where I live?
In part. The FDA grants interchangeable status, but actual pharmacy substitution is governed by state laws, which vary in their notification, consent, and recordkeeping requirements.
Why does interchangeability matter for drug prices?
Easier and more consistent substitution helps biosimilars gain market share faster, and greater competition drives prices down. That is why the shift toward treating interchangeability as standard could accelerate savings.
The Bottom Line
Biosimilar interchangeability has been one of the more misunderstood ideas in the biologics market. It was never a measure of quality, only a rule about substitution, and the framework around it is now being simplified. As the FDA moves toward treating all biosimilars as interchangeable, the path to competition and savings gets shorter, provided the infrastructure behind biosimilar development keeps pace. You can read more about my work supporting that infrastructure or get in touch.
This article is for general educational purposes and reflects publicly available regulatory information as of mid 2026. It is not medical, regulatory, or legal advice. Decisions about specific treatments should involve a qualified healthcare provider and pharmacist.
About Stephen Corba
Stephen (Steve) F. Corba Jr has spent more than fifteen years building the operational backbone of clinical research and pharmaceutical distribution. He founded Investigational Drug Delivery (IDD) in 2011 and has contributed operational expertise at VRC Medical Services, a women-owned specialty pharmaceutical distribution company. His focus is comparator sourcing, supply chain resilience, and the compliance and execution that keep research moving and help lower the cost of medicine. Learn more about Stephen or get in touch.
